Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Targeting the B-cell signalling pathway in CLL and MCL.

Sharma SP.

Lancet Oncol. 2013 Aug;14(9):e343. No abstract available.

PMID:
24058963
2.

Ibrutinib in chronic lymphocytic leukemia and B cell malignancies.

Brown JR.

Leuk Lymphoma. 2014 Feb;55(2):263-9. doi: 10.3109/10428194.2013.803226. Epub 2013 Jun 24. Review.

PMID:
23656200
3.

[Ibrutinib prescription in B-cell lymphoid neoplasms].

Dougé A, Ravinet A, Bay JO, Tournilhac O, Guièze R, Lemal R.

Bull Cancer. 2016 Feb;103(2):127-37. doi: 10.1016/j.bulcan.2015.12.003. Epub 2016 Jan 25. French.

PMID:
26822906
4.

Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies.

Gayko U, Fung M, Clow F, Sun S, Faust E, Price S, James D, Doyle M, Bari S, Zhuang SH.

Ann N Y Acad Sci. 2015 Nov;1358:82-94. doi: 10.1111/nyas.12878. Epub 2015 Sep 8. Review.

PMID:
26348626
5.

Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy.

de Rooij MF, Kuil A, Kater AP, Kersten MJ, Pals ST, Spaargaren M.

Blood. 2015 Apr 2;125(14):2306-9. doi: 10.1182/blood-2014-12-619163. No abstract available.

6.

Targeted therapy in chronic lymphocytic leukemia: past, present, and future.

Danilov AV.

Clin Ther. 2013 Sep;35(9):1258-70. doi: 10.1016/j.clinthera.2013.08.004. Review.

7.

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765).

Burger JA, Buggy JJ.

Leuk Lymphoma. 2013 Nov;54(11):2385-91. doi: 10.3109/10428194.2013.777837. Epub 2013 Aug 28. Review.

PMID:
23425038
8.

Ibrutinib: targeting the hidden CLL.

Awan FT.

Blood. 2014 May 22;123(21):3215-6. doi: 10.1182/blood-2014-04-565333. No abstract available.

9.

In vitro and In vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts.

Mollinedo F, de la Iglesia-Vicente J, Gajate C, Estella-Hermoso de Mendoza A, Villa-Pulgarin JA, de Frias M, Roué G, Gil J, Colomer D, Campanero MA, Blanco-Prieto MJ.

Clin Cancer Res. 2010 Apr 1;16(7):2046-54. doi: 10.1158/1078-0432.CCR-09-2456. Epub 2010 Mar 16.

10.

Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.

Marostica E, Sukbuntherng J, Loury D, de Jong J, de Trixhe XW, Vermeulen A, De Nicolao G, O'Brien S, Byrd JC, Advani R, McGreivy J, Poggesi I.

Cancer Chemother Pharmacol. 2015 Jan;75(1):111-21. doi: 10.1007/s00280-014-2617-3. Epub 2014 Nov 8.

PMID:
25381051
11.

Ibrutinib: first global approval.

Cameron F, Sanford M.

Drugs. 2014 Feb;74(2):263-71. doi: 10.1007/s40265-014-0178-8. Review.

PMID:
24464309
12.

FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia.

de Claro RA, McGinn KM, Verdun N, Lee SL, Chiu HJ, Saber H, Brower ME, Chang CJ, Pfuma E, Habtemariam B, Bullock J, Wang Y, Nie L, Chen XH, Lu DR, Al-Hakim A, Kane RC, Kaminskas E, Justice R, Farrell AT, Pazdur R.

Clin Cancer Res. 2015 Aug 15;21(16):3586-90. doi: 10.1158/1078-0432.CCR-14-2225.

13.

Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.

Chang BY, Francesco M, De Rooij MF, Magadala P, Steggerda SM, Huang MM, Kuil A, Herman SE, Chang S, Pals ST, Wilson W, Wiestner A, Spaargaren M, Buggy JJ, Elias L.

Blood. 2013 Oct 3;122(14):2412-24. doi: 10.1182/blood-2013-02-482125. Epub 2013 Aug 12.

14.

Chemotherapy of mantle cell lymphoma relapsed or refractory chronic lymphocytic leukaemia.

[No authors listed]

Prescrire Int. 2016 Apr;25(170):91. No abstract available.

PMID:
27186618
15.
16.

B-cell receptor inhibitors in chronic lymphocytic leukemia.

Flinn IW.

Clin Adv Hematol Oncol. 2011 Aug;9(8):605-6. No abstract available.

PMID:
22236988
17.

Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling.

McMullen JR, Boey EJ, Ooi JY, Seymour JF, Keating MJ, Tam CS.

Blood. 2014 Dec 11;124(25):3829-30. doi: 10.1182/blood-2014-10-604272. No abstract available.

18.

Inhibitors of B-cell receptor signaling for patients with B-cell malignancies.

Choi MY, Kipps TJ.

Cancer J. 2012 Sep-Oct;18(5):404-10. Review.

19.

Imbruvica®▾(ibrutinib) patient support programme for chronic lymphocytic leukaemia and mantle cell lymphoma.

Murthy V, Weaving S, Paneesha S.

Br J Nurs. 2017 May 25;26(10):S20-S25. doi: 10.12968/bjon.2017.26.10.S20.

PMID:
28541116
20.

Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling.

Roué G, López-Guerra M, Milpied P, Pérez-Galán P, Villamor N, Montserrat E, Campo E, Colomer D.

Clin Cancer Res. 2008 Nov 1;14(21):6907-15. doi: 10.1158/1078-0432.CCR-08-0388.

Supplemental Content

Support Center